Literature DB >> 15029793

A real-world way to manage real options.

Tom Copeland1, Peter Tufano.   

Abstract

Each corporate growth project is an option, in the sense that managers face choices--push ahead or pull back--along the way. Yet many companies hesitate to apply options theory to initiatives such as R&D and geographic expansion, partly because these "real" options are highly complex. In this article, the authors make the case that the complexity of real options can be eased through the use of a binomial valuation model. Many of the problems with real-options analysis stem from the use of the Black-Scholes-Merton model, which isn't suited to real options. Binomial models, by contrast, are simpler mathematically, and you can tinker with a binomial model until it closely reflects the project you wish to value. Suppose your company is considering investing in a new plant. To use the binomial model, you must create an "event tree" to figure out the full range of possible values for the plant during the project's lifetime--next year, at the end of the design phase, upon completion. Then you work backward from the value at completion, factoring in the various investments, to determine the value of the project today. These calculations provide you with numbers for all the possible future values of the option at the various points where a decision needs to be made on whether to continue with the project. The authors also address another criticism of real options: that gaps often arise between theoretical and realized values of options of all types. Such gaps may be largely the result of managers exercising options at the wrong time. To improve the way it manages its real options, a company can look out for the decision trigger points that correspond to the nodes on a binomial decision tree. The trigger points should not only tell managers when they need to decide on exercise but also specify rules governing the exercise decisions.

Mesh:

Year:  2004        PMID: 15029793

Source DB:  PubMed          Journal:  Harv Bus Rev        ISSN: 0017-8012


  2 in total

1.  Therapeutic hypothermia after pediatric cardiac arrest trials: the vanguard phase experience and implications for other trials.

Authors:  Victoria L Pemberton; Brittan Browning; Angie Webster; J Michael Dean; Frank W Moler
Journal:  Pediatr Crit Care Med       Date:  2013-01       Impact factor: 3.624

2.  Corporate social responsibility: a real options approach to the challenge of financial sustainability.

Authors:  Maria-Teresa Bosch-Badia; Joan Montllor-Serrats; Maria-Antonia Tarrazon-Rodon
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.